Jinhe Biotechnology(SZ:002688)2022-11-19 06:01Group 1: Financial Performance and Contracts - The company is currently undergoing a private placement, with announcements to be made according to regulatory procedures [1][2] - The cash flow situation has been disclosed in the company's financial reports [2] - The gross profit margin and net profit margin have increased compared to last year due to better vaccine sales [2][3] Group 2: Product Development and Market Strategy - The company is actively developing vaccines, with a focus on products like the dual vaccine for pigs and the brucellosis vaccine, expected to be registered by mid-next year [5][12] - The company plans to expand its production capacity for gentamicin, with a new project of 60,000 tons expected to be operational by the second half of next year [9][12] - The company is also preparing to launch a pet care division, focusing on deworming products [10][12] Group 3: Market Conditions and Challenges - The company has faced challenges due to rising raw material prices, leading to a 15% price increase for gentamicin [7] - The impact of the pandemic on sales was significant in 2020, but recovery is underway, with domestic sales of gentamicin gradually increasing [7][12] - The company is monitoring the competitive landscape, particularly regarding alternative products being developed by competitors [4][9] Group 4: Investor Relations and Communication - The company emphasizes transparency and timely communication with investors, adhering to legal disclosure requirements [11] - There is a commitment to improving investor relations and providing detailed updates on product registrations and market strategies [11][12] - The company is open to suggestions for enhancing investor communication and engagement [11]